Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myasthenia Gravis, Ocular: later-stage trial registry
1 of 2 indexed Myasthenia Gravis, Ocular trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Myasthenia Gravis, Ocular: 2 US clinical trials tracked, 1 recruiting.
Myasthenia Gravis, Ocular is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Myasthenia Gravis Foundation of America, running 1 of these trials.
Enrollment posture brief
Registry condition myasthenia-gravis-ocular
OPEN 1 | RECR 50% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Myasthenia Gravis, Ocular lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myasthenia Gravis, Ocular on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myasthenia Gravis, Ocular is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Myasthenia Gravis Foundation of America Global MG Patient Registry
Myasthenia Gravis Foundation of America
NCT06617741
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
argenx
NCT06558279
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myasthenia Gravis, Ocular records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myasthenia Gravis, Ocular trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myasthenia Gravis, Ocular page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Myasthenia Gravis, Ocular trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Myasthenia Gravis Foundation of America sponsors the most Myasthenia Gravis, Ocular trials on record, review their full trial history before evaluating a specific study. See Myasthenia Gravis Foundation of America's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myasthenia Gravis, Ocular condition card totals 2 registered trials; most-linked intervention Placebo PH20 SC; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.